Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, MA – December 6, 2022 Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a global confirmatory trial of the Corvia Atrial Shunt in heart failure […]
Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients TEWKSBURY, MA – JUNE 9, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced the closing of a $54 million equity financing from its existing investor syndicate. Funds will be utilized to support a […]
Landmark trial advances understanding of which HFpEF patients may benefit from atrial shunt therapy TEWKSBURY, MA – APRIL 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), announced publication of analyses from its global, phase III REDUCE LAP-HF II randomized trial of heart failure patients with preserved (HFpEF) […]
REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapy TEWKSBURY, MA – FEBRUARY 1, 2022 Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomized clinical trial, investigating the safety and efficacy of the Corvia® Atrial Shunt in […]
Large randomized, sham-controlled trial evaluates interatrial shunting in a heart failure population currently without effective treatment TEWKSBURY, MA – November 17, 2020 — Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), today announced completion of randomization in its REDUCE LAP-HF II global, pivotal trial. The trial is evaluating the […]
TEWKSBURY, MA – January 13, 2020— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the first Japanese patients were randomized in Toyama and Hyogo under a clinical trial authorization from the Pharmaceutical and Medical Device Agency (PMDA) in the REDUCE LAP-HF II trial. The Corvia InterAtrial […]
TEWKSBURY, MA – October 9, 2019— Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its InterAtrial Shunt Device (IASD) for heart failure.The IASD is the world’s first transcatheter device […]
Corvia Medical Enters Into Agreement With Edwards Lifesciences, The Global Leader In Structural Heart Innovation
Corvia Medical Announces Strong Positive One-Year Data From Reduce LAP-HF I Randomized, Sham-Controlled Clinical Trial
Corvia Medical Announces Enrollment of First Patients in Pivotal Trial of the IASD® System II for the Treatment of Heart Failure
